

Title (en)

ORAL COMPOSITION OF ANTI-TNF-ALPHA ANTIBODIES

Title (de)

ORALE ZUSAMMENSETZUNG VON ANTI-TNF-ALPHA-ANTIKÖRPERN

Title (fr)

COMPOSITION ORALE D'ANTICORPS ANTI-TNF ALPHA

Publication

EP 3490534 A1 20190605 (FR)

Application

EP 17749664 A 20170726

Priority

- FR 1657442 A 20160729
- EP 2017068918 W 20170726

Abstract (en)

[origin: WO2018019900A1] The present application relates to a pharmaceutical composition for oral administration, comprising a monoclonal anti-tumor necrosis factor alpha antibody (TNF α) and at least one or more pharmaceutically acceptable excipients selected from the group comprising: a carboxymethyl-dextran, a chitosan, a cyclodextrin, or a combination of same, as well as the use of said composition in the treatment of inflammatory diseases or autoimmune diseases.

IPC 8 full level

A61K 9/16 (2006.01); **A61K 9/19** (2006.01); **A61K 39/395** (2006.01)

CPC (source: EP US)

A61K 9/1652 (2013.01 - EP US); **A61K 9/19** (2013.01 - EP US); **A61K 39/39591** (2013.01 - EP US); **A61P 29/00** (2017.12 - EP US); **A61P 37/06** (2017.12 - EP US); **C07K 16/24** (2013.01 - EP US); **C07K 16/241** (2013.01 - US)

Citation (search report)

See references of WO 2018019900A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2018019900 A1 20180201; CA 3031033 A1 20180201; EP 3490534 A1 20190605; FR 3054444 A1 20180202; US 2019270801 A1 20190905

DOCDB simple family (application)

EP 2017068918 W 20170726; CA 3031033 A 20170726; EP 17749664 A 20170726; FR 1657442 A 20160729; US 201716320297 A 20170726